Cancer Science
HT-6184: A Novel Approach to Cancer Treatment
HT-6184: A Targeted Approach to Low-Risk Myelodysplastic Syndrome (MDS)
Understanding Myelodysplastic Syndrome (MDS)Myelodysplastic Syndrome (MDS) is a group of disorders characterized by ineffective blood cell production and an increased risk of progression to acute myeloid leukemia (AML).12 Patients with lower-risk MDS often experience anemia and require regular blood transfusions.13 HT-6184 is under investigation for its potential to modulate inflammation in the bone marrow by targeting the NLRP3 inflammasome, which may contribute to impaired erythropoiesis in MDS.14Preclinical studies suggest that inhibiting NLRP3 could help reduce inflammation and improve blood cell production, and the therapeutic potential of HT-6184 in MDS is being assessed in a phase 2 clinical trial in patients with very low, low and intermediate risk MDS.15Investigational Status: HT-6184 is investigational and is not currently approved for the treatment of patients with MDS. Data regarding its mechanism of action are based on preclinical studies. Halia is conducting a phase 2 clinical trial to assess the efficacy of HT-6184 in subjects with lower-risk MDS. This study is expected to be completed in early 2025.HT-6184: Investigating the Role of Inflammation in Cancer
The Dual Role of NLRP3 in Cancer
Inflammation plays a complex role in cancer development, acting as both a promoter and inhibitor of tumor growth.16 The NLRP3 inflammasome is involved in this process, contributing to the inflammatory microenvironment that may support tumor progression.17
HT-6184, a selective inhibitor of the NLRP3 inflammasome, is under investigation for its potential to reduce pro-tumorigenic inflammation while preserving anti-tumor immune responses.19
While preclinical studies have shown promising results, more research is needed to determine the clinical applicability of HT-6184 in cancer therapy.18,19
Investigational Status: HT-6184 is investigational and has not been approved as a treatment for cancer. The mechanisms of action described are based on preclinical research, and clinical trials are needed to evaluate its safety and efficacy in patients with cancer.
Obesity
Almost half of US adults are obese or severely obese. Lack of physical activity, unhealthy eating behavior, and, in some cases, genetics contribute to obesity. Halia is developing investigational treatments to combat obesity.
Pain and Rheumatoid Arthritis
Rheumatoid Arthritis (RA) is an autoimmune condition where the immune system—normally the body's defender against infection and disease—attacks its own tissues. This results in pain, swelling, stiffness, and loss of joint function. Halia is developing an investigational treatment for both RA and post-surgical pain.
Alzheimer's Disease
Alzheimer’s disease involves parts of the brain that control memory, language, problem-solving, and other thinking abilities. It can seriously affect a person’s ability to carry out daily activities. Halia is developing a potentially relevant pathway and investigational treatment for Alzheimer’s.
Parkinson's Disease
Parkinson’s disease is a progressive disorder that affects the nervous system and the parts of the body controlled by the nerves. Tremors, stiffness, or slowing of movement are typical symptoms. Halia is developing a potential brain-penetrant compound to treat the disease.